Related Experiment Videos

[General AL-amyloidosis: a rare complication in Waldenstrom macroglobulinemia]

I Zimmermann1, H J Gloor, S Rüttimann

  • 1Medizinische Abteilung, Kantonsspital Schaffhausen.

Praxis
|January 5, 2002
PubMed

Insights

Waldenström's macroglobulinemia (WM) is a rare IgM paraprotein disorder. In a rare case, amyloidosis developed 21 years after WM diagnosis, leading to organ failure and poor prognosis.

Area of Science:

  • Hematology
  • Oncology
  • Nephrology

Background:

  • Waldenström's macroglobulinemia (WM) is a rare lymphoplasmacytic lymphoma characterized by monoclonal IgM paraprotein.
  • WM typically follows an indolent course with less frequent renal complications compared to multiple myeloma.
  • Amyloidosis is an uncommon complication, occurring in less than 5% of patients with monoclonal IgM.

Observation:

  • A 65-year-old patient with asymptomatic WM, untreated for 21 years, developed amyloidosis.
  • The patient presented with nephrotic syndrome, renal failure, and heart failure secondary to amyloid deposition.
  • This case highlights a rare but severe association between WM and systemic amyloidosis.

Findings:

  • Amyloidosis developed two decades after the initial WM diagnosis, irrespective of disease duration or paraprotein levels.
  • Amyloid deposition led to progressive organ damage, manifesting as nephrotic syndrome and heart failure.
  • The development of amyloidosis in WM indicates a poor prognosis.

Implications:

  • The rare occurrence of amyloidosis in WM underscores the need for vigilance in monitoring for systemic complications.
  • Early chemotherapy's role in preventing amyloidosis in WM remains unknown and warrants further investigation.
  • Understanding the pathogenesis of amyloidosis in WM is crucial for improving patient outcomes and therapeutic strategies.

Related Concept Videos

Myasthenia Gravis ll: Pathophysiology01:22

Myasthenia Gravis ll: Pathophysiology

The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Rheumatic Heart Disease I: Introduction01:23

Rheumatic Heart Disease I: Introduction

Rheumatic heart disease or RHD is a chronic condition that results from rheumatic fever, causing permanent damage to the heart valves.Etiology and Risk FactorsIt primarily arises from rheumatic fever, an inflammatory disease that can develop after untreated or inadequately treated group A streptococcal (GAS) pharyngitis. Streptococcus spreads through direct contact with oral or respiratory secretions. While the bacteria are the causative agents, factors like malnutrition, overcrowding, poor...
Cytotoxic Edema: Pathophysiology01:21

Cytotoxic Edema: Pathophysiology

Cytotoxic edema is a form of cerebral edema characterized by intracellular swelling of neurons, astrocytes, and other glial cells. It develops when the mechanisms responsible for maintaining ionic gradients across the cell membrane become impaired. Under normal physiological conditions, the sodium–potassium ATPase actively transports sodium ions out of the cell and potassium ions into the cell, preserving osmotic balance and enabling electrical signaling. This pump requires a continuous supply...
Graves Disease II: Pathophysiology01:24

Graves Disease II: Pathophysiology

Graves’ disease is an autoimmune disorder characterized by the production of thyroid-stimulating immunoglobulins (TSI) that activate TSH receptors, leading to excessive synthesis and release of thyroid hormones (T3 and T4) and resulting in hyperthyroidism.Among all causes of hyperthyroidism, Graves’ disease is the most common and can happen at any age, though it is more frequent in women. It produces a hypermetabolic state with features such as weight loss, tachycardia, tremor, and heat...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...